Inventor · disambiguated record
Peter Sandner
Also filed as: SANDNER PETER
10 granted patents·25 pending applications·16 citations·filing 2004–2024
83Inventor score
Top patents by PatentIndex Score
35 records- 0190US12195448B2Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2023·Granted Jan 14, 2025·4 cites·18 claims
- 0289US10918639B2Combination containing SGC stimulators and mineralocorticoid receptor antagonistsBayer Pharma AG·Filed 2017·Granted Feb 16, 2021·3 cites·19 claims
- 0382US11331308B2Combination containing sGC activators and mineralocorticoid receptor antagonistsBayer Pharma AG·Filed 2017·Granted May 17, 2022·1 cites·13 claims
- 0475US2025026737A1Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2024·Application pending·0 cites
- 0572US10189856B2Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)HIRTH DIETRICH CLAUDIA·Filed 2011·Granted Jan 29, 2019·4 cites·7 claims
- 0671US9040566B2Adenosine A1 agonists for the treatment of glaucoma and ocular hypertensionKLAR JÜRGEN·Filed 2011·Granted May 26, 2015·2 cites·11 claims
- 0767US2022241255A1Combination containing sgc activators and mineralocorticoid receptor antagonistsBayer Pharma AG·Filed 2022·Application pending·0 cites
- 0866US11684621B2Combination containing sGC stimulators and mineralocorticoid receptor antagonistsBayer Pharma AG·Filed 2020·Granted Jun 27, 2023·0 cites·25 claims
- 0964US2023346777A1Use of sgc activators for the treatment of ophthalmologic diseasesBAYER AG·Filed 2023·Application pending·0 cites
- 1060US8304406B2Compounds for treating pulmonary hypertensionKLEIN MARTINA·Filed 2007·Granted Nov 6, 2012·2 cites·18 claims
- 1159US2022241273A1Use of sgc activators for the treatment of ophthalmologic diseasesBAYER AG·Filed 2022·Application pending·0 cites
- 1259US2010210643A1sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERSBAYER SCHERING PHARMA AG·Filed 2008·Application pending·0 cites
- 1357US10265314B2SGC stimulators in combination with additional treatment for the therapy of cystic fibrosisBayer Pharma AG·Filed 2014·Granted Apr 23, 2019·0 cites·8 claims
- 1457US2010010024A1Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertensionBAYER HEALTHCARE AG·Filed 2007·Application pending·0 cites
- 1555US2023201174A1Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseasesBAYER AG·Filed 2021·Application pending·0 cites
- 1651US2024051935A1Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2021·Application pending·0 cites
- 1751US2011092500A1Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairmentBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 1851US2014288079A1Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunctionBayer Pharma AG·Filed 2014·Application pending·0 cites
- 1950US2024109864A1Substituted pyrazolyl piperidine carboxylic acidsBAYER AG·Filed 2021·Application pending·0 cites
- 2050US2024101528A1Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2021·Application pending·0 cites
- 2149US2012058983A1Adenosine A1 agonists for the treatment of glaucoma and ocular hypertensionKLAR JUERGEN·Filed 2011·Application pending·0 cites
- 2247US11508483B2Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control groupADVERIO PHARMA GMBH·Filed 2019·Granted Nov 22, 2022·0 cites·10 claims
- 2347US2015306084A1Adenosine a1 agonists for the treatment of glaucoma and ocular hypertensionBAYER IP GMBH·Filed 2015·Application pending·0 cites
- 2446US2022128561A1Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)BAYER AG·Filed 2020·Application pending·0 cites
- 2546US2010184769A1Pde inhibitors for the treatment of hearing impairmentBAYER SCHERING PHARMA AG·Filed 2008·Application pending·0 cites
- 2646US2005222247A1Chroman derivativesBAYER HEALTHCARE AG·Filed 2004·Application pending·0 cites
- 2744US2021052528A1The use of sgc activators and sgc stimulators for the treatment of cognitive impairmentBAYER AG·Filed 2019·Application pending·0 cites
- 2844US2009176791A1Diaryl Ureas for Treating Pulmonary HypertensionBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 2944US2009186896A1PDE Inhibitors and Combinations Thereof for the Treatment of Urological DisordersBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 3043US2018169095A1The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)Bayer Pharma AG·Filed 2016·Application pending·0 cites
- 3143US2010035888A1Diaryl Urea for Treating Pulmonary HypertensionBater Healthcare AG·Filed 2006·Application pending·0 cites
- 3241US11439628B2Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseasesBAYER AG·Filed 2019·Granted Sep 13, 2022·0 cites·8 claims
- 3341US2008214654A1Substituted Benzyloxy-Phenylmethylamide DerivativesBAYER HEALTHCARE AG·Filed 2005·Application pending·0 cites
- 3441US2012022028A1Sgc stimulators or sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunctionSANDNER PETER·Filed 2010·Application pending·0 cites
- 3537US2013035340A1sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSISBAYER IP GMBH·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Sandner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →